The impact of salpingectomy and single-dose systemic methotrexate treatments on ovarian reserve in ectopic pregnancy

Loading...
Publication Logo

Date

2016

Authors

Cagdas Sahin
Enes Taylan
Ali Osman Akdemir
Banu Ozgurel
Dilek Taşkiran
Ahmet Mete Ergenoǧlu

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier Ireland Ltd

Open Access Color

Green Open Access

Yes

OpenAIRE Downloads

OpenAIRE Views

Publicly Funded

No
Impulse
Top 10%
Influence
Top 10%
Popularity
Top 10%

Research Projects

Journal Issue

Abstract

Objective To investigate the effects of salpingectomy and methotrexate treatments on ovarian reserve in ectopic pregnancy. Study design In this prospective study a total of 131 patients with ectopic pregnancy were divided into 3 groups of methotrexate (MTX) only (Group-1 n: 55) salpingectomy only (Group-2 n: 61) and salpingectomy following MTX (Group-3 n: 15). Pretreatment and post-treatment anti-Müllerian hormone (AMH) levels were evaluated. Results Significant differences in AMH levels were detected between group 1 and group 2 (2.52 ± 1.28 vs. 1.96 ± 1.66 p = 0.043) and group 1 and group 3 (2.52 ± 1.28 vs. 1.77 ± 0.76 p = 0.035) at one month postoperative. However these differences disappeared at the 3rd postoperative month. When AMH levels were compared within the same group postoperative one month AMH levels were significantly lower than the preoperative AMH levels only in group 3 (p = 0.03). However this difference also disappeared at the 3rd postoperative month. Conclusion Systemic single-dose methotrexate treatment unilateral salpingectomy and salpingectomy following methotrexate administration in ectopic pregnancy were reassuring based on pretreatment and post-treatment AMH levels. Current medical and surgical treatment approaches do not have an obvious negative effect on ovarian reserve. © 2019 Elsevier B.V. All rights reserved.

Description

Keywords

Ectopic Pregnancy, Methotrexate, Ovarian Reserve, Salpingectomy, Methotrexate, Muellerian Inhibiting Factor, Abortifacient Agents Nonsteroidal, Methotrexate, Methotrexate, Muellerian Inhibiting Factor, Abortive Agent, Adult, Article, Controlled Study, Ectopic Pregnancy, Female, Human, Major Clinical Study, Ovarian Reserve, Postoperative Period, Priority Journal, Prospective Study, Salpingectomy, Single Drug Dose, Treatment Outcome, Drug Effects, Ovary, Pregnancy, Pregnancy Ectopic, Young Adult, Abortifacient Agents Nonsteroidal, Adult, Female, Humans, Methotrexate, Ovarian Reserve, Ovary, Pregnancy, Prospective Studies, Salpingectomy, Treatment Outcome, Young Adult, methotrexate, Muellerian inhibiting factor, abortive agent, adult, Article, controlled study, ectopic pregnancy, female, human, major clinical study, ovarian reserve, postoperative period, priority journal, prospective study, salpingectomy, single drug dose, treatment outcome, drug effects, ovary, pregnancy, Pregnancy Ectopic, young adult, Abortifacient Agents Nonsteroidal, Adult, Female, Humans, Methotrexate, Ovarian Reserve, Ovary, Pregnancy, Prospective Studies, Salpingectomy, Treatment Outcome, Young Adult, Adult, Abortifacient Agents, Nonsteroidal, Ectopic pregnancy, Ovarian reserve, Ovary, Pregnancy, Ectopic, Salpingectomy, Young Adult, Methotrexate, Treatment Outcome, Pregnancy, Humans, Female, Prospective Studies, Ovarian Reserve

Fields of Science

03 medical and health sciences, 0302 clinical medicine

Citation

WoS Q

Scopus Q

OpenCitations Logo
OpenCitations Citation Count
20

Source

European Journal of Obstetrics & Gynecology and Reproductive Biology

Volume

205

Issue

Start Page

150

End Page

152
PlumX Metrics
Citations

CrossRef : 18

Scopus : 23

PubMed : 8

Captures

Mendeley Readers : 38

Google Scholar Logo
Google Scholar™
OpenAlex Logo
OpenAlex FWCI
2.6722

Sustainable Development Goals